Therapeutic strategies targeting ALK5 have been considered particularly in the context of diseases characterized by excessive fibrosis, such as idiopathic pulmonary fibrosis, liver fibrosis, cardiovascular disease, and certain cancers [32–34]. Here, TGFBR1 is linked to Hepatic fibrosis.